Business Editors/Health/Medical Writers
TORONTO–(BUSINESS WIRE)–May 7, 2003
Biovail Corporation (NYSE:BVF) (TSX:BVF) announced today that it has achieved favorable formulary coverage for recently launched Cardizem(R) LA, a graded once-daily controlled release medication for t…
By Julius A. Karash, The Kansas City Star, Mo. Knight Ridder/Tribune Business News
Feb. 19–Aventis Pharmaceuticals and Andrx Corp. have agreed to pay a combined $80 million to settle claims of conspiring to keep a generic form of Cardizem CD off the market.
The money is earmarked for consumers, state agencies and insuran…
Business & Health/Medical Editors
TORONTO–(BW HealthWire)–July 24, 2001
Biovail Corporation (NYSE:BVF)(TSE:BVF)
– Combination of unique Cardizem(r) XL delivery profile and nighttime dosing
demonstrates clinically significant improvement over placebo and morning dosing
– Innovative formulation addresses circadian variation in blood pressure with
optima…
WASHINGTON, Oct. 21 /U.S. Newswire/ — The deadline to file claims
in the Cardizem(r) CD antitrust case has been extended through Nov.
15, 2003. Although tens of thousands of claims have already been
made, the deadline has been extended to give consumers more time to
act on their legal rights.
Most Popular
13 Job Interview Mistakes To Avoid
10 Jobs That Pay $30 An Hour
3 Questions No Job Seeker Ever Wants To Be Asked?
Pu…
TORONTO — Biovail Corporation (NYSE, TSX: BVF) today announced that its subsidiary, Biovail Laboratories International SRL (BLS), has reached a settlement agreement with Watson Pharmaceuticals, Inc. (NYSE: WPI), with respect to patent litigation against Watso…
More than $300,000 is in the mail to Oklahoma consumers who overpaid for a commonly prescribed heart medication, Attorney General Drew Edmondson said.
Checks were mailed last week to consumers who purchased Cardizem CD or …
TORONTO, ONTARIO, May 7, 2003 (CCNMatthews via COMTEX)
Biovail Corporation (NYSE:BVF) (TSX:BVF) announced today that it has achieved favorable formulary coverage for recently launched Cardizem(R) LA, a graded once-daily controlled release medication for the treatment of hypertension. Biovail has signed agreements giving Cardizem(R) LA a favorable formulary position with a number of Pharmacy Benefits Managers (PBMs) and Managed Care Organizations (MCOs) providing prescr…
Business Editors, Health & Medical Writers
TORONTO–(BW HealthWire)–June 17, 2002
Biovail Corporation (NYSE:BVF)(TSE:BVF) announced today that it has received an Approvable Letter from the United States Food and Drug Administration (FDA) for Cardizem(R) XL (diltiazem HCL extended release tablets), a novel medication for the treatment of hypertension. The New Drug Application was submitted in August 2001. In the Cardizem(R)…
Business Editors/Health/Medical Writers
NEW YORK–(BUSINESS WIRE)–May 16, 2003
New Graded-Release Diltiazem Formulation Outperforms “ACE” from HOPE
Trial
In one of the first head-to-head trials to compare the advantages of two blood pressure treatments administered at night,…
Business Editors, Health & Medical Writers
TORONTO–(BUSINESS WIRE)–Feb. 7, 2003
Biovail Corporation (NYSE:BVF)(TSX:BVF)
– Cardizem(R) LA “graded release” provides 24-hour blood pressure control
– Convenience and flexibility of once-daily dosing
– Clinical trials indicate safety and tolerabi…
